St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval, receipt of European CE Mark clearance and market launch of the QuickSite XL bipolar, left-heart lead to treat heart failure patients. The QuickSite XL lead is used in cardiac resynchronization therapy (CRT) procedures for heart failure patients with average to large size veins. The lead's heightened S-shape is designed to provide stability and allow physicians to successfully position it in bigger veins. St. Jude Medical (http://phx.corporate-ir.net/phoenix.zhtml?c=73836&p=irol-newsreleases#)